Evidence map›Paper›PMID 32329963›Full record

Trial reportJournal of diabetes investigation2020

Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study.

Tomoe Kinoshita, Masashi Shimoda, Koji Nakashima, Yoshiro Fushimi, Yurie Hirata, Akihito Tanabe, Fuminori Tatsumi, Hidenori Hirukawa, Junpei Sanada, Kenji Kohara and 9 more

Open access · goldAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of diabetes investigation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 15 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 15 pooled it
8.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 15 syntheses or guidelines pooled it, 100 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Trial
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 1 institution in 1 country.

Tomoe KinoshitaDivision of Diabetes, Metabolism and Endocrinology, Kawasaki Medical School, Kurashiki, Japan.
Masashi ShimodaDivision of Diabetes, Metabolism and Endocrinology, Kawasaki Medical School, Kurashiki, Japan.ORCID https://orcid.org/0000-0002-4223-9613
Koji NakashimaDivision of Diabetes, Metabolism and Endocrinology, Kawasaki Medical School, Kurashiki, Japan.
Yoshiro FushimiDivision of Diabetes, Metabolism and Endocrinology, Kawasaki Medical School, Kurashiki, Japan.
Yurie HirataDivision of Diabetes, Metabolism and Endocrinology, Kawasaki Medical School, Kurashiki, Japan.
Akihito TanabeDivision of Diabetes, Metabolism and Endocrinology, Kawasaki Medical School, Kurashiki, Japan.
Fuminori TatsumiDivision of Diabetes, Metabolism and Endocrinology, Kawasaki Medical School, Kurashiki, Japan.
Hidenori HirukawaDivision of Diabetes, Metabolism and Endocrinology, Kawasaki Medical School, Kurashiki, Japan.ORCID https://orcid.org/0000-0002-4826-2574
Junpei SanadaDivision of Diabetes, Metabolism and Endocrinology, Kawasaki Medical School, Kurashiki, Japan.
Kenji KoharaDivision of Diabetes, Metabolism and Endocrinology, Kawasaki Medical School, Kurashiki, Japan.
Shintaro IrieDivision of Diabetes, Metabolism and Endocrinology, Kawasaki Medical School, Kurashiki, Japan.
Tomohiko KimuraDivision of Diabetes, Metabolism and Endocrinology, Kawasaki Medical School, Kurashiki, Japan.ORCID https://orcid.org/0000-0003-3986-9494
Yoshiko NakamuraDivision of Diabetes, Metabolism and Endocrinology, Kawasaki Medical School, Kurashiki, Japan.ORCID https://orcid.org/0000-0003-0063-2596
Momoyo NishiokaDivision of Diabetes, Metabolism and Endocrinology, Kawasaki Medical School, Kurashiki, Japan.
Atsushi ObataDivision of Diabetes, Metabolism and Endocrinology, Kawasaki Medical School, Kurashiki, Japan.
Shuhei NakanishiDivision of Diabetes, Metabolism and Endocrinology, Kawasaki Medical School, Kurashiki, Japan.ORCID https://orcid.org/0000-0003-2640-9632
Tomoatsu MuneDivision of Diabetes, Metabolism and Endocrinology, Kawasaki Medical School, Kurashiki, Japan.
Kohei KakuKawasaki Medical School, Kurashiki, Japan.ORCID https://orcid.org/0000-0003-1574-0565
Hideaki KanetoDivision of Diabetes, Metabolism and Endocrinology, Kawasaki Medical School, Kurashiki, Japan.ORCID https://orcid.org/0000-0001-7898-1943
Kawasaki Medical School · JP

Funding

Kawasaki Medical School Research Project Grant 29G-002
6 · The paper itself

Abstract

AIMS/

introductionNon-alcoholic fatty liver disease (NAFLD) is often observed in individuals with type 2 diabetes mellitus, and it is known that the presence of type 2 diabetes mellitus leads to the aggravation of NAFLD. The aim of this study was to compare the possible effects of three kinds of oral hypoglycemic agents on NAFLD in individuals with type 2 diabetes mellitus. MATERIALS AND

methodsWe carried out a prospective clinical trial (a randomized and open-label study) in patients with type 2 diabetes mellitus and NAFLD. A total of 98 patients were randomly allocated either to the dapagliflozin (n = 32), pioglitazone (n = 33) or glimepiride (n = 33) group, and the patients took these drugs for 28 weeks. The primary end-point was the change of the liver-to-spleen ratio on abdominal computed tomography.

resultsThere was no difference in baseline clinical characteristics among the three groups. Dapagliflozin, pioglitazone and glimepiride ameliorated hyperglycemia similarly. Bodyweight and visceral fat area were significantly decreased only in the dapagliflozin group. Serum adiponectin levels were markedly increased in the pioglitazone group compared with the other two groups. Dapagliflozin and pioglitazone, but not glimepiride, significantly increased the liver-to-spleen ratio, and the effects of dapagliflozin and pioglitazone on the liver-to-spleen ratio were comparable.

conclusionsThe present study showed that the decrease of visceral fat area and the increase of adiponectin level contributed to the improvement of NAFLD in patients with type 2 diabetes mellitus. Furthermore, dapagliflozin and pioglitazone exerted equivalent beneficial effects on NAFLD in patients with type 2 diabetes mellitus, although it seemed that these two drugs had different mechanisms of action.

Indexed as

Benzhydryl CompoundsBiomarkersBlood GlucoseCase-Control StudiesDiabetes Mellitus, Type 2FemaleFollow-Up StudiesGlucosidesGlycated HemoglobinHumansHypoglycemic AgentsIntra-Abdominal FatMaleMiddle AgedNon-alcoholic Fatty Liver DiseasePioglitazoneBenzhydryl CompoundsBiomarkersBlood GlucosedapagliflozinglimepirideGlucosidesGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsPioglitazoneSodium-Glucose Transporter 2 InhibitorsSulfonylurea CompoundsNon-alcoholic fatty liver diseaseSodium-glucose cotransporter 2 inhibitorType 2 diabetes mellitus

Identifiers

PMID32329963
PMCPMC7610105
OpenAlexW3019568499

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.